Clinical trials
Observational Schizophrenia trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2011 | 2 |
| 2013 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aziende Chimiche Riunite Angelini Francesco S.p.A | 2 |
| Hoffmann-La Roche | 2 |
| Otsuka Pharmaceutical Europe Ltd | 2 |
| University of Bari | 2 |
| AstraZeneca | 1 |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 1 |
| Carmen Concerto | 1 |
| IRCCS Centro San Giovanni di Dio Fatebenefratelli | 1 |
| IRCCS San Raffaele | 1 |
| Janssen-Cilag International NV | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Schizophrenia | 18 |
| Mental Disorders | 2 |
| Obsessive-Compulsive Disorder | 2 |
| Antisocial Personality Disorder | 1 |
| Anxiety Disorders | 1 |
| Bipolar Disorder | 1 |
| Generalized Anxiety Disorder | 1 |
| Inflammation | 1 |
| Intellectual Disability | 1 |
| Major Depressive Disorder | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.